Insulet Appoints Jonathan Mazelsky to Board of Directors

Details

Mazelsky as a new independent director, effective July 1, 2026. Mr. Mazelsky, who has extensive experience in the healthcare and technology sectors, will stand for election by stockholders at the Company's 2027 Annual Meeting. His background includes serving as President and CEO of IDEXX Laboratories, Inc., where he led significant growth and innovation. The appointment is expected to bring valuable insights and expertise to Insulet as it continues to expand its Omnipod insulin pump technology.

Items reported

About Insulet Corporation

Insulet Corporation is a prominent healthcare company specializing in medical devices, with a key focus on diabetes management. Its flagship product, the Omnipod Insulin Management System, is an innovative, tubeless insulin pump that offers users freedom and flexibility, addressing the lifelong needs of individuals with diabetes. The system is acclaimed for its discreet, water-resistant pods, which deliver continuous insulin delivery without the constraints of traditional insulin pumps. Insulet Corporation plays a crucial role in the medical technology industry by enhancing patient experiences and outcomes. Headquartered in Acton, Massachusetts, Insulet Corporation continues to pioneer advancements in insulin delivery solutions, directly impacting healthcare providers and improving the quality of life for diabetes patients globally. Its market significance is underscored by its commitment to innovation and accessibility, bridging the gap between technology and patient-centric care in the rapidly evolving healthcare sector.